Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation
- PMID: 16417416
- DOI: 10.1089/jwh.2006.15.35
Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation
Abstract
Background: Apparently discrepant findings have been reported by the Women's Health Initiative (WHI) trial compared with observational studies of postmenopausal hormone therapy (HT) and coronary heart disease (CHD).
Methods: We prospectively examined the relation of HT to CHD, according to timing of hormone initiation relative to age and time since menopause. Participants were postmenopausal women in the Nurses' Health Study, with follow-up from 1976 to 2000. Information on hormone use was ascertained in biennial, mailed questionnaires. We used proportional hazards models to calculate multivariable adjusted relative risks (RR) and 95% confidence intervals (CI). We also conducted sensitivity analyses to determine the possible influence of incomplete capture of coronary events occurring shortly after initiation of HT.
Results: Women beginning HT near menopause had a significantly reduced risk of CHD (RR = 0.66, 95% CI 0.54-0.80 for estrogen alone; RR = 0.72, 95% CI 0.56-0.92 for estrogen with progestin). In the subgroup of women demographically similar to those in the WHI, we found no significant relation between HT and CHD among women who initiated therapy at least 10 years after menopause (RR = 0.87, 95% CI 0.69-1.10 for estrogen alone; RR = 0.90, 95% CI 0.62-1.29 for estrogen with progestin). Among women who began taking hormones at older ages, we also found no relation between current use of estrogen alone and CHD (for women aged 60+ years, RR = 1.07, 95% CI 0.65-1.78), although there was a suggestion of possible reduced risk for combined HT (RR = 0.65, 95% CI 0.31-1.38). In sensitivity analyses, we found that the incomplete capture of coronary events occurring shortly after initiation of HT could not explain our observation of a reduced risk of coronary disease for current users of HT.
Conclusions: These data support the possibility that timing of HT initiation in relation to menopause onset or to age might influence coronary risk.
Comment in
-
Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing?J Womens Health (Larchmt). 2006 Jan-Feb;15(1):51-3. doi: 10.1089/jwh.2006.15.51. J Womens Health (Larchmt). 2006. PMID: 16417418 No abstract available.
Similar articles
-
Menopause and stroke and the effects of hormonal therapy.Climacteric. 2007 Oct;10 Suppl 2:27-31. doi: 10.1080/13697130701550903. Climacteric. 2007. PMID: 17882669 Review.
-
Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25. Am J Epidemiol. 2009. PMID: 19468078
-
Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study.J Glaucoma. 2007 Oct-Nov;16(7):598-605. doi: 10.1097/IJG.0b013e318064c82d. J Glaucoma. 2007. PMID: 18091177
-
Postmenopausal hormones and coronary artery disease: potential benefits and risks.Climacteric. 2007 Oct;10 Suppl 2:21-6. doi: 10.1080/13697130701578631. Climacteric. 2007. PMID: 17882668 Review.
-
Postmenopausal hormone therapy and migraine headache.J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956. J Womens Health (Larchmt). 2003. PMID: 14709191
Cited by
-
The association of female reproductive factors with history of cardiovascular disease: a large cross-sectional study.BMC Public Health. 2024 Jun 17;24(1):1616. doi: 10.1186/s12889-024-19130-4. BMC Public Health. 2024. PMID: 38886693 Free PMC article.
-
Pre-diagnostic free androgen and estradiol levels influence heart failure risk in both women and men: A prospective cohort study in the UK Biobank.Eur J Heart Fail. 2024 Mar;26(3):540-550. doi: 10.1002/ejhf.3189. Epub 2024 Mar 25. Eur J Heart Fail. 2024. PMID: 38528787
-
Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy.JAMA Netw Open. 2023 Dec 1;6(12):e2348213. doi: 10.1001/jamanetworkopen.2023.48213. JAMA Netw Open. 2023. PMID: 38100102 Free PMC article.
-
Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case-control study.Front Pharmacol. 2023 Oct 10;14:1220174. doi: 10.3389/fphar.2023.1220174. eCollection 2023. Front Pharmacol. 2023. PMID: 37881187 Free PMC article.
-
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?Circulation. 2023 Feb 14;147(7):597-610. doi: 10.1161/CIRCULATIONAHA.122.061559. Epub 2023 Feb 13. Circulation. 2023. PMID: 36780393 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
